CN1315513C - Traditional Chinese medicine powder for treating mastitis of dairy cattle - Google Patents
Traditional Chinese medicine powder for treating mastitis of dairy cattle Download PDFInfo
- Publication number
- CN1315513C CN1315513C CNB2004100732896A CN200410073289A CN1315513C CN 1315513 C CN1315513 C CN 1315513C CN B2004100732896 A CNB2004100732896 A CN B2004100732896A CN 200410073289 A CN200410073289 A CN 200410073289A CN 1315513 C CN1315513 C CN 1315513C
- Authority
- CN
- China
- Prior art keywords
- mastitis
- chinese medicine
- traditional chinese
- treatment
- milk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 43
- 239000000843 powder Substances 0.000 title claims abstract description 13
- 208000004396 mastitis Diseases 0.000 title abstract description 38
- 241000283690 Bos taurus Species 0.000 title abstract description 25
- 235000013365 dairy product Nutrition 0.000 title abstract description 5
- 239000004863 Frankincense Substances 0.000 claims abstract description 8
- 208000031462 Bovine Mastitis Diseases 0.000 claims description 20
- 241000717739 Boswellia sacra Species 0.000 claims description 7
- 241000628997 Flos Species 0.000 claims description 7
- 241001057584 Myrrha Species 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 6
- 235000013336 milk Nutrition 0.000 abstract description 31
- 239000008267 milk Substances 0.000 abstract description 31
- 210000004080 milk Anatomy 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 15
- 238000002360 preparation method Methods 0.000 abstract description 9
- 210000004369 blood Anatomy 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 8
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000017531 blood circulation Effects 0.000 abstract description 3
- 239000012535 impurity Substances 0.000 abstract description 3
- 238000010298 pulverizing process Methods 0.000 abstract description 3
- 230000008961 swelling Effects 0.000 abstract description 3
- 230000006651 lactation Effects 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 2
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 235000003717 Boswellia sacra Nutrition 0.000 abstract 1
- 240000007551 Boswellia serrata Species 0.000 abstract 1
- 235000012035 Boswellia serrata Nutrition 0.000 abstract 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 240000007890 Leonurus cardiaca Species 0.000 abstract 1
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 241000237502 Ostreidae Species 0.000 abstract 1
- 240000004534 Scutellaria baicalensis Species 0.000 abstract 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 abstract 1
- 238000003759 clinical diagnosis Methods 0.000 abstract 1
- 238000001035 drying Methods 0.000 abstract 1
- 230000000337 effect on mastitis Effects 0.000 abstract 1
- 230000035876 healing Effects 0.000 abstract 1
- 235000020636 oyster Nutrition 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
- 210000000582 semen Anatomy 0.000 abstract 1
- 238000007873 sieving Methods 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 230000003115 biocidal effect Effects 0.000 description 8
- 210000000481 breast Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000000987 immune system Anatomy 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 4
- 108010050904 Interferons Proteins 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940079322 interferon Drugs 0.000 description 4
- 229960005322 streptomycin Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010060891 General symptom Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 238000013196 antibiotherapy Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 244000309465 heifer Species 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 210000005075 mammary gland Anatomy 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000697 sensory organ Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 239000000273 veterinary drug Substances 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100026720 Interferon beta Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001741 anti-phlogistic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940023964 caffeine and sodium benzoate Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 210000000630 fibrocyte Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- JWBPVFVNISJVEM-UHFFFAOYSA-M sodium caffeine benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2C JWBPVFVNISJVEM-UHFFFAOYSA-M 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002132 β-lactam antibiotic Substances 0.000 description 1
- 229940124586 β-lactam antibiotics Drugs 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a traditional Chinese medicine powder for treating mastitis of dairy cows, which comprises the following traditional Chinese medicine components in parts by weight: 35-45 g of honeysuckle, 35-45 g of fructus forsythiae, 35-45 g of dandelion, 15-25 g of herba violae, 25-35 g of radix bupleuri, 25-35 g of scutellaria baicalensis, 15-25 g of semen brassicae, 25-35 g of keel, 25-35 g of oyster, 55-65 g of motherwort, 10-20 g of frankincense and 10-20 g of myrrh. The preparation method comprises sun drying the above Chinese medicinal materials, removing impurities, pulverizing, sieving with 80 mesh sieve, and tightly packaging with double-layer plastic bag according to 400g per bag. Clinical diagnosis and treatment practices prove that the traditional Chinese medicine powder has remarkable curative effect on mastitis, has the effects of clearing away heat and toxic materials, promoting blood circulation, removing blood stasis, eliminating stagnation, reducing swelling, promoting lactation and the like, and can quickly recover the milk yield to a normal level after healing, keep stable and prevent relapse.
Description
Technical field
The invention belongs to tcm field, relate to a kind of veterinary drug, particularly a kind of Chinese powder medicine mastitis that is used for the treatment of bovine mastitis disappears.
Background technology
Mastitis be in the world milk cattle cultivating industry sickness rate the highest, popular the fastest, one of maximum disease causes damage.Join in a common effort meter according to U.S.'s milk, clinical type bovine mastitis sickness rate is up to 50%, and total incidence can account for 70% of whole cows.Because it is more to cause the paathogenic factor of bovine mastitis, the infective pathogen type is more assorted, therefore how effectively to prevent and treat various types of mastitis to have become world subject.Correlational study both domestic and external in recent years report has highlighted methods such as the antibiotherapy that is used to prevent and treat bovine mastitis, recombinant vaccine, interferon, yolk antibody, and the pluses and minuses between them are compared.
One, bovine mastitis is the very big disease of world's milk product industry hazardness, it is reported that mastitis comprise to the harm that dairy causes: directly cause the minimizing of milk yield; The cattle milk that quilt is outwelled because milk modification and drug residue are used people's anorexia; Some Niu Wufa cure and the loss that is eliminated and caused; The spending of medical care expenses during the treatment mastitis; Nurse the required extra labour force spending of disease cattle etc.The sickness rate of most countries mastitis is about 40% in the world, and every cattle decreased average milk amount is about 15%.Since the nineties, be subjected to this to influence annual economic loss in the U.S. and reach 2,000,000,000 dollars, about 200 dollars of the annual losses of average every cattle.Even more serious is because some mastitis has infectiousness, and the infection of several cattle just often can cause spreading of whole cattle farm mastitis.From pathology, mastitis are mammary gland tissue a kind of inflammatory reaction processes for extraneous bad conditions such as antibacterial, fungus, mycete, chemicals, warm stimulation and mechanical injuries.This process comprises: the leukocytic quantity in the concentration of immune protein and mammary gland tissue and Ruzhong in the elevating blood.Studies show that the mastitis in China pasture are all caused by pathogenic microorganism more than 80%.
Two, the treatment measure of mastitis
1, the antibiotic use of antibiotic is a kind of treatment means that generally adopts both at home and abroad at present.Clinical commonly used drug generally includes following a few class: beta-lactam antibiotic (being penicillin medicine), aminoglycoside medicaments, macrolide antibiotic and lincomycin etc.The main dry milk phase therapy of using promptly after milking for the last time age of sucking, is injected the antibiotic of doses to each breast district of every cattle.Have and report that this method can comparatively effectively control the infection of infectiousness pathogenic bacterium such as staphylococcus aureus, streptococcus etc., and to the microbial mastitis effect of the large intestine in the environment and not obvious.Also have some antibiotic oral formulations also can reach the effect of sterilization, antiinflammatory in addition.Usually effect is comparatively desirable in the early stage to use antibiotherapy, but also there are many unfavorable factors in it: (1) is prone to Drug resistance and drug resistance.(2) the single medicine antimicrobial spectrum is wide inadequately, often needs several antibiotic mixing to use, and spends higher.(3) cause some other side effect,, influence appetite etc. as alteration of intestinal flora.(4) cause the residual and milch cow drug disposition savings of milk Chinese medicine, jeopardize human health indirectly.
What 2, recombinant vaccine adopted the vaccine control mastitis is safer, effective method.It excites the intravital specific antibody of disease cattle to reach the purpose of bactericidal antiphlogistic by injecting inactivated bacteria or weak malicious Seedling.Utilizing the modal problem of vaccine control bovine mastitis is the variation of bacterial antigens, and the structure that antibacterial constantly changes virulence factor makes immune system always lag behind antibacterial when producing new antibody.Cause vaccine fine 1 year effect, 1 year ineffective.Research worker finds that the gram negative bacteria cell wall contains a kind of " general cAg " and will be exposed to immune system at the fastest this position of exponential phase of bacterial growth afterwards.At this moment antibody is with it in conjunction with reaching preventive and therapeutic effect.For example the J5 bacillus coli vaccine utilizes this principle development.Also have a class vaccine also to utilize the general cAg of gram negative bacteria to design.It is reported that this vaccine makes gram negative bacteria commit suiside by to containing the conversion of sucrose-6 fructose-transferring enzyme substrate plasmid, collects these negative bacterium and prepares vaccine under sucrose induction.It is said that it does not damage the immunogenicity of vaccine, can not damage the significant points of correct stimulation animal immune system, can not produce alternate, non-natural vaccine antigen.Used chemical inducer is edible sucrose, thereby needn't remove.Can reduce simultaneously endotoxin content in the body greatly, stimulating immune system is resisted the caused bovine mastitises of gram negative bacteria such as escherichia coli.But because the paathogenic factor complexity, present vaccine is difficult to various mastitis are all played excellent curative.
3. the immunocyte and the non-immunocyte of reorganization cattle gamma interferon (rboIFN-γ) body can synthesize and secrete the micromolecular polypeptide class factor, and they can regulate the various kinds of cell physiological function, are called cytokine.Present known interleukin, interferon (Interferon, IFN), colony stimulating factor, tumor necrosis factor, transforming growth factor etc. all are cytokines that immunocyte produces, they play very important regulating and controlling effect in immune system, also can cause pathological reaction under abnormal conditions.IFN is the cytokine of finding at first, as far back as nineteen fifty-seven, people such as Issacs find that the cell of viral infection produces a kind of factor, can resist the infection of virus, duplicating of viral interference, thereby called after interferon are according to its source and structure, IFN can be divided into IFN-α, IFN-β and IFN-γ, they are produced by leukocyte, fibrocyte and activating T cell respectively.IFN also has antitumor except that antivirus action is arranged, immunomodulating, control cell proliferation and cause effect such as heating.After cloning IFN-γ first in 1986, the method for relevant in the last few years IFN-γ treatment mastitis is subjected to people's attention gradually.IFN-γ is one section and contains 143 amino acid whose glycoproteins that molecular weight is between 14-18kDa.It is to be produced by NK cell that is activated and T emiocytosis.Sordillo etc. have carried out the experiment of heifer immunity, prevent coliform property mastitis with rboIFN-γ.It is 42% that the result uses the matched group mortality rate of placebo, and treatment group milch cow all survives.Show that interferon-can suppress the growth of coliform, strengthen the immunity of nascent heifer coliform.The rboIFN-γ dosage of again newborn pond being injected has carried out testing (Snider etc., 1992) after this.Studies show that: the suitable dose of rboIFN-γ is about 105U/ breast district, and SCC value and constituent content all do not have obvious variation in the sample of suckling this moment.The SCC value can significantly raise when the injected dose in the every newborn pond of rboIFN-γ surpasses 107U, and lactose content and the pH value in the milk component all can descend simultaneously, and milk quality is reduced.RboIFN-γ experiment in vitro finds that a certain amount of rboIFN-γ can strengthen the phagocytic activity of neutrophil and macrophage, but does not influence its sterilizing ability.The mechanism of the bovine mastitis of rboIFN-γ method treatment at present still imperfectly understands, it must with the receptors bind competence exertion biological activity of its high-affinity.Along with the enhancing of present consumer health's consciousness, carry out " relieved milk " in China also imperative comprehensively.
Be to replace said method, develop that the pharmaceutical treatment bovine mastitis is imperative in a kind of treatment, relate to the key technology brainstorm project of " original new drug and the modernization of Chinese medicine ", " the milk industry develops " and " food safety " these three Ministry of Science and Technology's propositions.
Summary of the invention
The object of the invention is to provide a kind of Chinese powder medicine that is used for the treatment of bovine mastitis, and this medicine all adopts Chinese medicine to form, and can effectively treat bovine mastitis.
The objective of the invention is to be achieved through the following technical solutions:
A kind of Chinese powder medicine that is used for the treatment of bovine mastitis is characterized in that this Chinese patent medicine is made up of the Chinese medicine ingredients of following weight parts: Flos Lonicerae 35~45g, Fructus Forsythiae 35~45g, Herba Taraxaci 35~45g, Herba Violae 15~25g, Radix Bupleuri 25~35g, Radix Scutellariae 25~35g, Semen Sinapis Albae 15~25g, Os Draconis 25~35g, Concha Ostreae 25~35g, Herba Leonuri 55~65g, Olibanum 10~20g, Myrrha 10~20g.
Its preparation method is, above-mentioned Chinese medicine is dried, chooses clean impurity, pulverizing, crosses 80 mesh sieves, tightly seals with the double-layer plastic bag by every bag 400g to get final product.
Chinese powder medicine of the present invention facts have proved that through clinic diagnosis mastitis disappears evident in efficacy, and it has heat-clearing and toxic substances removing, the blood circulation promoting and blood stasis dispelling eliminating stagnation, and effects such as detumescence stimulating milk secretion, and also milk yield returns to normal level very soon after curing, and keeps stable, is difficult for recurrence.
The specific embodiment
The pharmacodynamics test of this Chinese patent medicine that provides below in conjunction with the inventor and acute and long term toxicity test and specific embodiment are described in further detail the present invention.
1. pharmacodynamics test
Flos Lonicerae, Fructus Forsythiae, Herba Taraxaci, Herba Violae, Radix Scutellariae heat-clearing and toxic substances removing, sterilizing and anti-virus in the prescription of the present invention; Inside and outside Radix Scutellariae, Radix Glycyrrhizae, dried summer regulating cold and heat, the reconciliation; Olibanum, Myrrha, Herba Leonuri blood circulation promoting and blood stasis dispelling, anti-inflammatory analgetic; Herba Leonuri, the Radix Angelicae Dahuricae, Semen Sinapis Albae, Os Draconis, Concha Ostreae, the soft eliminating stagnation of Bulbus Fritillariae Thunbergii, inducing diuresis to remove edema; Radix Glycyrrhizae, Fructus Aurantii antiallergic, protect taste, harmonizing the functional activities of vital QI, full side plays disease-resistant former altogether, blood stasis dispelling blood, the pain that relieves the pain, clear swelling soft or hard knot, the merit in lactogenesis road is the potion good medicine of treatment milch cow acute and chronic mastitis on the present veterinary clinic.
The Chinese medicine of this treatment bovine mastitis looses with matched group, group, middle amount group, a large amount of group experimentize in a small amount, and proving that Chinese medicine of the present invention is diffusing has significant effect (seeing table) to sick cattle cure rate
Group | Dosage (g/ days) | Sick cattle number (head) | Cure rate (%) | Remarks |
Matched group | 0 | ?10 | ?0 | |
Organize in a small amount | 300 | ?10 | ?90 | Administration time is longer, and total dosage is big |
Middle amount group | 400 | ?10 | ?100 | The medication phase is short, and total dosage is little |
A large amount of groups | 500 | ?10 | ?60 |
2. animal acute toxicity test
Once irritate each 20 of stomach mices with the dose of the tolerant Cmax of animal (3g/ml), 0.8ml, male and female half and half were observed 7 days continuously, did not take place dead.Dosage is the 120g/kg body weight, is equivalent to 179.1 times of clinical consumption.At viewing duration, do not find that animal has obvious poisoning symptom.
3. long-term toxicity test for animals
Rat is irritated stomach mastitis disappear continuous four months of 5g/kg/d, 15g/kg/d (be equivalent to clinical administration dosage 7.4,22.2 times) respectively, the general activity behind the two dosage group rat medicines, and the mental status, hair, feces etc. show no obvious abnormalities.Peripheral hemogram before and after the administration comprises that erythrocyte, leukocyte and classification, hemoglobin, packed cell volume all fluctuate in normal range.Three livers (SGPT, SGOT), kidney (blood urea nitrogen, creatinine) functional parameter be there is no obvious influence.During off-test, the content of total protein, albumin, alkali phosphatase is compared no significant difference with matched group in the animal serum.Electrocardioscopy is all no abnormal.Each main organs macroscopy is not seen morphological changes of various tissue components such as obvious enlargement, hyperemia, necrosis.The weight coefficient of the heart, liver, spleen, lung, kidney, thymus, adrenal gland, uterus, testis is compared with matched group, no significant difference.Histopathologic examination there is no unusual.The above presentation of results mastitis comparison safety that disappears there is no obvious toxic-side effects in institute's amount of reagent scope.(raw data is kept at animal and veterinary institute of Xibei Univ. of Agricultural ﹠ Forest Science ﹠ Technology).
4. the mastitis clinical practice report of (loosing) that disappears
Contrast test: with the milk cattle is example, is divided into three groups, and I group is with " mastitis disappears " treatment, and the II group is with the quiet notes treatment of penicillin, every day every consumption 600 million international units, the III group is treated with streptomycin, every day, every consumption 8g the results are shown in Table 1.
Table 1 " mastitis dissipation ", penicillin, the scorching effect table of streptomycin treatment dairy cow breast
Group | Treatment cattle number (head) | Cure number (head) | Cure rate (%) |
Mastitis dissipation (I group) | 30 | ?29 | ?96.7 |
Penicillin (II group) | 30 | ?22 | ?73.3 |
Streptomycin (III group) | 30 | ?21 | ?70.0 |
As can be seen from Table 1, the scorching effect of " mastitis dissipation " treatment dairy cow breast is obvious.
In the past, the clinical treatment mammitis of cow mainly used antibiotic, hormone and chemical synthetic drug, so brought a series of problems.Increase as Resistant strain, endocrine dysfunction, antibiotic and residue of veterinary drug exceed standard etc., badly influence human health.Along with China joined WTO, consumers in general require more and more higher to milk quality, propose the requirement of antibiotic-free milk, noresidue milk.At this situation, from JIUYUE, 1998 to 2004 year April, the applicant uses this Chinese medicine preparation mastitis treatment bovine mastitis 1283 examples that disappear, and total effective rate reaches more than 96%.
5. specific embodiment
Embodiment 1:
According to technical scheme of the present invention, the best preparation that this Chinese medicine that is used for the treatment of bovine mastitis looses is made up of the Chinese medicine ingredients of following weight parts: Flos Lonicerae 40g, Fructus Forsythiae 40g, Herba Taraxaci 40g, Herba Violae 20g, Bulbus Fritillariae Thunbergii 15g, Radix Angelicae Dahuricae 25g, Fructus Aurantii 40g, Radix Glycyrrhizae 20g, Radix Bupleuri 30g, Radix Scutellariae 30g, Semen Sinapis Albae 20g, Os Draconis 30g, Concha Ostreae 30g, Herba Leonuri 60g, Olibanum 15g, Myrrha 15g.
Its preparation method is that above-mentioned Chinese medicine is dried, chooses clean impurity, pulverizing, crosses 80 mesh sieves, tightly seals with the double-layer plastic bag by every bag 400g to get final product.
Embodiment 2:
This preparation that is used for the treatment of the Chinese powder medicine of bovine mastitis is made up of the Chinese medicine ingredients of following weight parts: Flos Lonicerae 35g, Fructus Forsythiae 35g, Herba Taraxaci 35g, Herba Violae 15g, Radix Bupleuri 25g, Radix Scutellariae 25g, Semen Sinapis Albae 15g, Os Draconis 25g, Concha Ostreae 25g, Herba Leonuri 55g, Olibanum 10g, Myrrha 10g.
Its preparation method is with embodiment 1.
Embodiment 3:
This preparation that is used for the treatment of the Chinese powder medicine of bovine mastitis is made up of the Chinese medicine ingredients of following weight parts: Flos Lonicerae 45g, Fructus Forsythiae 45g, Herba Taraxaci 45g, Herba Violae 25g, Radix Bupleuri 35g, Radix Scutellariae 35g, Semen Sinapis Albae 25g, Os Draconis 35g, Concha Ostreae 35g, Herba Leonuri 65g, Olibanum 20g, Myrrha 20g.
Its preparation method is with embodiment 1.
If be used for producing in batches, can be by the proportional amplification of above-mentioned prescription.
Prescription of the present invention is used in combination with the Western medicine XIAOZHONGLING, and then curative effect is better, and its prescription is as follows:
10% glucose injection 1000.0
5% calcirm chloride injization 250.0
10% caffeine and sodium benzoate injection 30.0
10% sodium salicylate injection 150.0
Once a day, quiet notes, for three days on end.
6. adaptation symptom
The early stage milk character of clinical type mastitis is unusual, thin, includes ziega or floccule, and what have is mixed with blood or pus, and the milk that has is discharged not smooth, and lactation amount reduces or stops.The middle and late stage breast is red, swollen, hot, bitterly, the lymphonodi mammarici enlargement.Most of milch cow is except that above-mentioned symptom, also with General Symptomies such as lassitude, appetite minimizing, fervescence.
The general clinical symptoms of latent mammitis is not obvious, and sense organ checks that milk does not have ANOMALOUS VARIATIONS, only shows the milk amount usually and reduces gradually, and most alcohol testings are positive.
7. using method
Mastitis (loosing) the each 400g that disappears, boiled water reconstitutes, and waits temperature and gavages every day 1-2 time.The person that has the General Symptoms is used in combination antibiotic, after General Symptoms disappears, takes mastitis again and disappears to keep in 1-3 days and consolidate curative effect, in case recurrence.
8. concrete case
Case on June 28th, 1,1999, light a certain the 6 years old Fresian in Yangling District Li Tai township, main suit: find both sides breast redness when milking before 3 days, please local veterinary use penicillin, streptomycin, kanamycin etc. still ineffective, and lassitude occur, loss of appetite.Check: bilateral breast is red, swollen, hot, bitterly, the lymphonodi supramammarici enlargement.Treatment disappears with mastitis and sooner or later respectively obeys 400g, and that the swelling has gone down is more than half for breast during the next day further consultation, and the reuse mastitis disappears 400g/ day, logotype 4 days, recovery from illness.
Case 2, on April 5 calendar year 2001,5 years old milch cow of Xingping City Sang Zhen Cao is examined the main suit: the milk amount descends to some extent recently, the milk sense organ is normal, but milk shed rejects after with alcohol testing, further check, and milk acidity is 20 ° of T, belong to alcohol positive milk, high acidity should be latent mammitis.Mastitis for oral administration 3 bags that disappear, the next day after, the milk acceptance(check), the milk amount is also gone up to some extent.
Claims (2)
1. Chinese powder medicine that is used for the treatment of bovine mastitis is characterized in that this Chinese powder medicine is made up of the Chinese medicine ingredients of following weight parts: Flos Lonicerae 35~45g, Fructus Forsythiae 35~45g, Herba Taraxaci 35~45g, Herba Violae 15~25g, Radix Bupleuri 25~35g, Radix Scutellariae 25~35g, Semen Sinapis Albae 15~25g, Os Draconis 25~35g, Concha Ostreae 25~35g, Herba Leonuri 55~65g, Olibanum 10~20g, Myrrha 10~20g.
2. the Chinese powder medicine that is used for the treatment of bovine mastitis as claimed in claim 1 is characterized in that this Chinese patent medicine is made up of the Chinese medicine ingredients of following weight parts: Flos Lonicerae 40g, Fructus Forsythiae 40g, Herba Taraxaci 40g, Herba Violae 20g, Bulbus Fritillariae Thunbergii 15g, Radix Angelicae Dahuricae 25g, Fructus Aurantii 40g, Radix Glycyrrhizae 20g, Radix Bupleuri 30g, Radix Scutellariae 30g, Semen Sinapis Albae 20g, Os Draconis 30g, Concha Ostreae 30g, Herba Leonuri 60g, Olibanum 15g, Myrrha 15g.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100732896A CN1315513C (en) | 2004-11-18 | 2004-11-18 | Traditional Chinese medicine powder for treating mastitis of dairy cattle |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100732896A CN1315513C (en) | 2004-11-18 | 2004-11-18 | Traditional Chinese medicine powder for treating mastitis of dairy cattle |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1634361A CN1634361A (en) | 2005-07-06 |
CN1315513C true CN1315513C (en) | 2007-05-16 |
Family
ID=34846826
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100732896A Expired - Fee Related CN1315513C (en) | 2004-11-18 | 2004-11-18 | Traditional Chinese medicine powder for treating mastitis of dairy cattle |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1315513C (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101411757B (en) * | 2008-12-12 | 2011-04-20 | 河北农业大学 | Injection for treating milk cattle mastitis and preparation method thereof |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101301389B (en) * | 2008-07-07 | 2010-10-13 | 赵守财 | Chinese medicinal composition for treating mammilla and lacteal cistern neoplasm disease of milk cattle and preparation and use thereof |
CN101780205B (en) * | 2010-03-24 | 2011-08-10 | 安徽农业大学 | Traditional Chinese medicine compound transdermal patch for treating mastitis of dairy cattle and preparation method thereof |
CN101947258B (en) * | 2010-04-12 | 2011-07-20 | 湖南圣雅凯生物科技有限公司 | Film-spraying agent for treating bovine mastitis |
CN103720930B (en) * | 2013-11-15 | 2016-07-06 | 北安市飞龙动物药厂 | A kind of Chinese medicine composition treating bovine mastitis |
CN105168770A (en) * | 2015-09-06 | 2015-12-23 | 王璐 | Veterinary drug for treating mastopathy of dairy cows |
CN106176955A (en) * | 2016-07-22 | 2016-12-07 | 太仓市爱农奶牛专业合作社 | A kind of antiinflammatory treating mammitis of cow and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1533782A (en) * | 2003-04-01 | 2004-10-06 | 林 赵 | Preparation method of dairy cattle mammitis anhinflammation powder |
-
2004
- 2004-11-18 CN CNB2004100732896A patent/CN1315513C/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1533782A (en) * | 2003-04-01 | 2004-10-06 | 林 赵 | Preparation method of dairy cattle mammitis anhinflammation powder |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101411757B (en) * | 2008-12-12 | 2011-04-20 | 河北农业大学 | Injection for treating milk cattle mastitis and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN1634361A (en) | 2005-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102225127B (en) | Traditional Chinese medicine composite for treating mastitis of dairy cattle | |
CN102579597B (en) | Chinese herbal compound prescription for preventing and curing mammitis of mammalian livestock and method for preparing same | |
CN1315513C (en) | Traditional Chinese medicine powder for treating mastitis of dairy cattle | |
CN101972391A (en) | Medicinal composition used for treating swine mastitis and preparation method thereof | |
CN102274355B (en) | Externally applied medicament for treating foot-and-mouth disease in pigs | |
CN104523897B (en) | A kind of enema medicament composition for treating piglet epidemic diarrhea | |
CN101612335A (en) | Be used to Chinese medicine composition of preventing and treating mammitis of cow and preparation method thereof | |
CN108743709A (en) | The new application of the composition of preventing piglet diarrhea, the preparation method of composition and barley worm lipid extracts | |
CN101209304A (en) | Chinese medicinal granule with clearing heat and detoxication, blood-nourishing and dysentery-stopping efficacy | |
CN110882345B (en) | Traditional Chinese medicine composition for preventing and treating postpartum abdominal pain of dairy cows and preparation method thereof | |
CN103893300B (en) | A kind of Chinese medicine composition treating cow endometritis and preparation method and application | |
CN106109908A (en) | A kind of mongolian medicine compositions treating sheep babesiasis | |
CN1660274A (en) | Combination of lmedication for treatig mastitis of cow and preparation method | |
CN105663256A (en) | Ultramicro traditional Chinese medicine for preventing and treating lactation reduction and redness and swelling of breasts of dairy cows | |
CN101209315A (en) | Chinese medicinal injection with antimicrobial and anti-inflammation, milk-smoothing and mass-dissipating efficacy | |
CN104606627B (en) | A kind of pharmaceutical composition for treating grice diarrhoea and preparation method thereof | |
AU2021105905A4 (en) | A Pharmaceutical Composition for Treating Diarrhea Of Piglet And Its Preparation Method | |
CN111588773B (en) | Traditional Chinese medicine composition for preventing and treating newborn piglet diarrhea through sow medicine taking and application thereof | |
CN103861007A (en) | Chinese herbal medicine compound preparation for treating diarrhea of chicken | |
CN103768182B (en) | A kind of Chinese medicinal perfusion liquid and its preparation method and application | |
CN107582650A (en) | A kind of Chinese medicine composition for being used to prevent and treat sow mastitis | |
CN115607614B (en) | Traditional Chinese medicine composition for treating colibacillosis of livestock and poultry and preparation method thereof | |
AU2021103716A4 (en) | An Enema Pharmaceutical Composition For Treating Diarrhea Of Piglet | |
CN113082140B (en) | Traditional Chinese medicine compound for treating acute mastitis of dairy cows and preparation method thereof | |
CN1927349A (en) | Traditional Chinese medicine for treating rheumatism and its preparing process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |